When Science Races: the Standard of Care and Medical Negligence in the Times of Covid-19

Abdulrahman A and others, ‘The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort’ (2021) 10 Infectious Diseases and Therapy <https://doi.org/10.1007/s40121-021-00397-8> accessed 28 February 2021. Abdulrahman A and others, ‘The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort’ ( 2021 ) 10 Infectious Diseases and Therapy <https://doi.org/10.1007/s40121-021-00397-8> accessed 28 February 2021. Search in Google Scholar

Act No. 378/2007 Coll., on Pharmaceuticals. Act No. 378/2007 Coll., on Pharmaceuticals. Search in Google Scholar

Act No. 372/2011 Coll., on Health Services and the Conditions of Their Provision. Act No. 372/2011 Coll., on Health Services and the Conditions of Their Provision. Search in Google Scholar

American College of Rheumatology, ‘Hydroxychloroquine (Plaquenil)’ (updated April 2020) <https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Hydroxychloroquine-Plaquenil> accessed 28 February 2021. American College of Rheumatology ‘Hydroxychloroquine (Plaquenil)’ (updated April 2020) <https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Hydroxychloroquine-Plaquenil> accessed 28 February 2021. Search in Google Scholar

Battegay M and others, ‘2019-Novel Coronavirus (2019-nCoV): Estimating the Case Fatality Rate: A Word of Caution’ (7 February 2020) Swiss Medical Weekly <https://smw.ch/article/doi/smw.2020.20203> accessed 20 February 2021. Battegay M and others, ‘2019-Novel Coronavirus (2019-nCoV): Estimating the Case Fatality Rate: A Word of Caution’ ( 7 February 2020 ) Swiss Medical Weekly <https://smw.ch/article/doi/smw.2020.20203> accessed 20 February 2021. Search in Google Scholar

BBC ‘Coronavirus: Hydroxychloroquine Ineffective Says Fauci’ (29 July 2020) <https://www.bbc.com/news/world-us-canada-53575964> accessed 28 February 2021. BBC ‘Coronavirus: Hydroxychloroquine Ineffective Says Fauci’ ( 29 July 2020 ) <https://www.bbc.com/news/world-us-canada-53575964> accessed 28 February 2021. Search in Google Scholar

Beaubien J, ‘WHO Halts Hydroxychloroquine Trial over Safety Concerns’ (NPR, 25 May 2020) <https://www.npr.org/sections/coronavirus-live-updates/2020/05/25/861913688/who-halts-hydroxychloroquine-trial-over-safety-concerns?t=1614538942824> accessed 28 February 2021. Beaubien J ‘WHO Halts Hydroxychloroquine Trial over Safety Concerns’ ( NPR 25 May 2020 ) <https://www.npr.org/sections/coronavirus-live-updates/2020/05/25/861913688/who-halts-hydroxychloroquine-trial-over-safety-concerns?t=1614538942824> accessed 28 February 2021. Search in Google Scholar

Branswell H, ‘Why “Flattening the Curve” May Be the World’s Best Bet to Slow the Ccoronavirus’ (11 March 2020) STAT Magazine <https://www.statnews.com/2020/03/11/flattening-curve-coronavirus/> accessed 20 February 2021. Branswell H ‘Why “Flattening the Curve” May Be the World’s Best Bet to Slow the Ccoronavirus’ ( 11 March 2020 ) STAT Magazine <https://www.statnews.com/2020/03/11/flattening-curve-coronavirus/> accessed 20 February 2021. Search in Google Scholar

Brazier M and Cave E, Medicine, Patients, and the Law (6th ed, Manchester University Press, 2016). Brazier M Cave E Medicine, Patients, and the Law ( 6th ed , Manchester University Press , 2016 ). Search in Google Scholar

Cathey L, ‘Timeline: Tracking Trump Alongside Scientific Developments on Hydroxychloroquine’ (ABC News 8 August 2020) <https://abcnews.go.com/Health/timeline-tracking-trump-alongside-scientific-developments-hydroxychloroquine/story?id=72170553> accessed 28 February 2021. Cathey L ‘Timeline: Tracking Trump Alongside Scientific Developments on Hydroxychloroquine’ ( ABC News 8 August 2020 ) <https://abcnews.go.com/Health/timeline-tracking-trump-alongside-scientific-developments-hydroxychloroquine/story?id=72170553> accessed 28 February 2021. Search in Google Scholar

Chen P-J, Chao C-M, and Lai C-C, ‘Clinical Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients’ (2020) Journal of Infection <https://doi.org/10.1016/j.jinf.2020.12.005> accessed 28 February 2021. Chen P-J Chao C-M Lai C-C ‘Clinical Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients’ ( 2020 ) Journal of Infection <https://doi.org/10.1016/j.jinf.2020.12.005> accessed 28 February 2021. Search in Google Scholar

‘Coronavirus (Covid-19)’ New England Journal of Medicine <https://www.nejm.org/coronavirus> accessed 28 February 2021. ‘Coronavirus (Covid-19)’ New England Journal of Medicine <https://www.nejm.org/coronavirus> accessed 28 February 2021. Search in Google Scholar

Dabbous HM and others, ‘Efficacy of Favipiravir in COVID-19 Treatment: A Multi-Center Randomized Study’ (2021) 166(3) Archives of Virology 949 <https://doi.org/10.1007/s00705-021-04956-9> accessed 28 February 2021. Dabbous HM and others, ‘Efficacy of Favipiravir in COVID-19 Treatment: A Multi-Center Randomized Study’ ( 2021 ) 166 ( 3 ) Archives of Virology 949 <https://doi.org/10.1007/s00705-021-04956-9> accessed 28 February 2021. Search in Google Scholar

Drugs.com, ‘Hydroxychloroquine’ (2020) <https://www.drugs.com/monograph/hydroxychloroquine.html> accessed 28 February 2021. Drugs.com ‘Hydroxychloroquine’ ( 2020 ) <https://www.drugs.com/monograph/hydroxychloroquine.html> accessed 28 February 2021. Search in Google Scholar

Electronic Medicines Compendium, ‘Dexamethasone 2mg Tablets’ (updated 19 May 2020) <https://www.medicines.org.uk/emc/product/5411/smpc#INDICATIONS> accessed 28 February 2021. Electronic Medicines Compendium ‘Dexamethasone 2mg Tablets’ (updated 19 May 2020 ) <https://www.medicines.org.uk/emc/product/5411/smpc#INDICATIONS> accessed 28 February 2021. Search in Google Scholar

Electronic Medicines Compendium, ‘Dexamethasone 3.3mg/ml Solution for Injection’ (updated 20 February 2020) <https://www.medicines.org.uk/emc/product/4659/smpc#gref> accessed 28 February 2021. Electronic Medicines Compendium ‘Dexamethasone 3.3mg/ml Solution for Injection’ (updated 20 February 2020 ) <https://www.medicines.org.uk/emc/product/4659/smpc#gref> accessed 28 February 2021. Search in Google Scholar

Enserink M, ‘Update: “A Bit Chaotic:” Christening of New Coronavirus and Its Disease Name Create Confusion’ (12 February 2020) Science <https://www.sciencemag.org/news/2020/02/bit-chaotic-christening-new-coronavirus-and-its-disease-name-create-confusion> accessed 20 February 2021. Enserink M ‘Update: “A Bit Chaotic:” Christening of New Coronavirus and Its Disease Name Create Confusion’ ( 12 February 2020 ) Science <https://www.sciencemag.org/news/2020/02/bit-chaotic-christening-new-coronavirus-and-its-disease-name-create-confusion> accessed 20 February 2021. Search in Google Scholar

European Commission. Directorate-General for Health and Food Safety, ‘Study on Off-Label Use of Medicinal Products in the European Union’ (9 September 2019) <https://data.europa.eu/doi/10.2875/464022> accessed 20 February 2021. European Commission. Directorate-General for Health and Food Safety ‘Study on Off-Label Use of Medicinal Products in the European Union’ ( 9 September 2019 ) <https://data.europa.eu/doi/10.2875/464022> accessed 20 February 2021. Search in Google Scholar

European Medicines Agency, ‘Assessment Report EMEA/H/A-5(3)1500’ (17 September 2020) <https://www.ema.europa.eu/en/documents/other/dexamethasone-covid19-article-53-procedure-assessment-report_en.pdf> accessed 28 February 2021. European Medicines Agency ‘Assessment Report EMEA/H/A-5(3)1500’ ( 17 September 2020 ) <https://www.ema.europa.eu/en/documents/other/dexamethasone-covid19-article-53-procedure-assessment-report_en.pdf> accessed 28 February 2021. Search in Google Scholar

European Medicines Agency, ‘EMA Endorses Use of Dexamethasone in COVID-19 Patients on Oxygen or Mechanical Ventilation’ (18 September 2020) <https://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation> accessed 28 February 2021. European Medicines Agency ‘EMA Endorses Use of Dexamethasone in COVID-19 Patients on Oxygen or Mechanical Ventilation’ ( 18 September 2020 ) <https://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation> accessed 28 February 2021. Search in Google Scholar

European Medicines Agency, ‘EMA Reviewing Data on Monoclonal Antibody Use for COVID-19’ (2 April 2021) <https://www.ema.europa.eu/en/news/ema-reviewing-data-monoclonal-antibody-use-covid-19> accessed 28 February 2021. European Medicines Agency ‘EMA Reviewing Data on Monoclonal Antibody Use for COVID-19’ ( 2 April 2021 ) <https://www.ema.europa.eu/en/news/ema-reviewing-data-monoclonal-antibody-use-covid-19> accessed 28 February 2021. Search in Google Scholar

European Medicines Agency, ‘EMA’s Final Opinion Confirms Restrictions on Use of Linear Gadolinium Agents in Body Scans’ (19 December 2017) <https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents> accessed 15 March 2022. European Medicines Agency ‘EMA’s Final Opinion Confirms Restrictions on Use of Linear Gadolinium Agents in Body Scans’ ( 19 December 2017 ) <https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents> accessed 15 March 2022. Search in Google Scholar

Food and Drug Administration, ‘Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19’ (21 November 2020) <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19> accessed 28 February 2021. Food and Drug Administration ‘Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19’ ( 21 November 2020 ) <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19> accessed 28 February 2021. Search in Google Scholar

Food and Drug Administration, ‘FDA Approves First Treatment for COVID-19’ (22 October 2020) <https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19> accessed 28 February 2021. Food and Drug Administration ‘FDA Approves First Treatment for COVID-19’ ( 22 October 2020 ) <https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19> accessed 28 February 2021. Search in Google Scholar

Food and Drug Administration, ‘FDA Drug Safety Communication, Safety Announcement’ (24 April 2020) <https://www.fda.gov/media/137250/download> accessed 28 February 2021. Food and Drug Administration ‘FDA Drug Safety Communication, Safety Announcement’ ( 24 April 2020 ) <https://www.fda.gov/media/137250/download> accessed 28 February 2021. Search in Google Scholar

Fraser N and others, ‘Preprinting a Pandemic: The Role of Preprints in the COVID-19 Pandemic’ (bioRxiv, 23 May 2020) <https://www.biorxiv.org/content/10.1101/2020.05.22.111294v1.full> accessed 28 February 2021. Fraser N and others, ‘Preprinting a Pandemic: The Role of Preprints in the COVID-19 Pandemic’ (bioRxiv, 23 May 2020 ) <https://www.biorxiv.org/content/10.1101/2020.05.22.111294v1.full> accessed 28 February 2021. Search in Google Scholar

Garcés HH, Belenguer Muncharaz A, and Zaragoza Crespo R, ‘Noninvasive mechanical ventilation and COVID-19. Minimizing dispersion’ (2020) 44(8) Medicina Intensiva 520 <https://medintensiva.org/en-noninvasive-mechanical-ventilation-covid-19-minimizing-articulo-S2173572720301508> accessed 20 February 2021. Garcés HH Belenguer Muncharaz A Zaragoza Crespo R ‘Noninvasive mechanical ventilation and COVID-19. Minimizing dispersion’ ( 2020 ) 44 ( 8 ) Medicina Intensiva 520 <https://medintensiva.org/en-noninvasive-mechanical-ventilation-covid-19-minimizing-articulo-S2173572720301508> accessed 20 February 2021. Search in Google Scholar

Gautret P and others, ‘Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial’ (2020) 56(1) International Journal of Antimicrobial Agents 105949 <https://doi.org/10.1016/j.ijantimicag.2020.105949> accessed 28 February 2021. Gautret P and others, ‘Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial’ ( 2020 ) 56 ( 1 ) International Journal of Antimicrobial Agents 105949 <https://doi.org/10.1016/j.ijantimicag.2020.105949> accessed 28 February 2021. Search in Google Scholar

Goold I and Herring J, Great Debates in Medical Law and Ethics (2nd ed, Palgrave, 2018). Goold I Herring J Great Debates in Medical Law and Ethics ( 2nd ed , Palgrave , 2018 ). Search in Google Scholar

Gottlieb RL and others, ‘Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial’ (2021) 325(7) JAMA 632 <https://doi.org/10.1001/jama.2021.0202> accessed 28 February 2021. Gottlieb RL and others, ‘Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial’ ( 2021 ) 325 ( 7 ) JAMA 632 <https://doi.org/10.1001/jama.2021.0202> accessed 28 February 2021. Search in Google Scholar

Haškovcová H, ‘Lege artis v proměnách času [Lege Artis and Its Changes over Time]’ in Ptáček R, Bartůněk P and Mach J (eds), Lege artis v medicíně [Lege Artis in Medicine] (1st ed, Grada 2013). Haškovcová H ‘Lege artis v proměnách času [Lege Artis and Its Changes over Time]’ in Ptáček R Bartůněk P Mach J (eds), Lege artis v medicíně [Lege Artis in Medicine] ( 1st ed , Grada 2013 ). Search in Google Scholar

Infectious Diseases Society of America, ‘Anti-SARS-CoV-2 Monoclonal Antibodies’ (last reviewed 1 March 2022) <https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/monoclonal-antibodies/> accessed 28 February 2021. Infectious Diseases Society of America ‘Anti-SARS-CoV-2 Monoclonal Antibodies’ (last reviewed 1 March 2022 ) <https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/monoclonal-antibodies/> accessed 28 February 2021. Search in Google Scholar

Ivashchenko AA and others, ‘AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial’ (2020) 73(3) Clinical Infectious Diseases <https://doi.org/10.1093/cid/ciaa1176> accessed 28 February 2021. Ivashchenko AA and others, ‘AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial’ ( 2020 ) 73 ( 3 ) Clinical Infectious Diseases <https://doi.org/10.1093/cid/ciaa1176> accessed 28 February 2021. Search in Google Scholar

Jin Y-H and others, ‘A Rrapid Advice Guideline for the Diagnosis and Treatment of 2019 Novel Coronavirus (2019-nCoV) Infected Pneumonia (Standard Version)’ (2020) 7(4) Military Medical Research <https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-020-0233-6> accessed 20 February 2021. Jin Y-H and others, ‘A Rrapid Advice Guideline for the Diagnosis and Treatment of 2019 Novel Coronavirus (2019-nCoV) Infected Pneumonia (Standard Version)’ ( 2020 ) 7 ( 4 ) Military Medical Research <https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-020-0233-6> accessed 20 February 2021. Search in Google Scholar

Komaroff A, ‘The Tragedy of Long COVID’ (Harvard Health Blog, 1 March 2021) <https://www.health.harvard.edu/blog/the-tragedy-of-the-post-covid-long-haulers-2020101521173> accessed 02 March 2021. Komaroff A ‘The Tragedy of Long COVID’ ( Harvard Health Blog , 1 March 2021 ) <https://www.health.harvard.edu/blog/the-tragedy-of-the-post-covid-long-haulers-2020101521173> accessed 02 March 2021. Search in Google Scholar

Lewis K and others, ‘The Efficacy and Safety of Hydroxychloroquine for COVID-19 Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Trials’ (2021) PLOS ONE <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244778> accessed 28 February 2021. Lewis K and others, ‘The Efficacy and Safety of Hydroxychloroquine for COVID-19 Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Trials’ ( 2021 ) PLOS ONE <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244778> accessed 28 February 2021. Search in Google Scholar

Liu J and others, ‘Hydroxychloroquine, A Less Toxic Derivate of Chloroquine, Is Effective in Inhibiting SARS-CoV-2 Infection in vitro’ (2020) 6(16) Cell Discovery <https://www.nature.com/articles/s41421-020-0156-0> accessed 28 February 2021. Liu J and others, ‘Hydroxychloroquine, A Less Toxic Derivate of Chloroquine, Is Effective in Inhibiting SARS-CoV-2 Infection in vitro’ ( 2020 ) 6 ( 16 ) Cell Discovery <https://www.nature.com/articles/s41421-020-0156-0> accessed 28 February 2021. Search in Google Scholar

Lopes MI and others, ‘Beneficial Effects of Colchicine for Moderate to Severe COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial’ (2021) 7 <https://doi.org/10.1136/rmdopen-2020-001455> accessed 28 February 2021. Lopes MI and others, ‘Beneficial Effects of Colchicine for Moderate to Severe COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial’ ( 2021 ) 7 <https://doi.org/10.1136/rmdopen-2020-001455> accessed 28 February 2021. Search in Google Scholar

Lovelace B Jr and Breuninger K, ‘Trump Says He Takes Hydroxychloroquine to Prevent Coronavirus Infection Even Though It’s an Unproven Treatment’ (CNBC 18 May 2020) <https://www.cnbc.com/2020/05/18/trump-says-he-takes-hydroxychloroquine-to-prevent-coronavirus-infection.html> accessed 28 February 2021. Lovelace B Jr Breuninger K ‘Trump Says He Takes Hydroxychloroquine to Prevent Coronavirus Infection Even Though It’s an Unproven Treatment’ ( CNBC 18 May 2020 ) <https://www.cnbc.com/2020/05/18/trump-says-he-takes-hydroxychloroquine-to-prevent-coronavirus-infection.html> accessed 28 February 2021. Search in Google Scholar

Mehra MR and others, ‘Hydroxychloroquine or Chloroquine with or without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis’ (2020) The Lancet <https://doi.org/10.1016/S0140-6736(20)31180-6> accessed 28 February 2021. Mehra MR and others, ‘Hydroxychloroquine or Chloroquine with or without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis’ ( 2020 ) The Lancet <https://doi.org/10.1016/S0140-6736(20)31180-6> accessed 28 February 2021. Search in Google Scholar

Mehra MR, Ruschitzka F, and Patel A N, ‘Retraction – Hydroxychloroquine or Chloroquine with or without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis’ (2020) 395(10240) The Lancet 1820 <https://doi.org/10.1016/S0140-6736(20)31324-6> accessed 28 February 2021. Mehra MR Ruschitzka F Patel A N ‘Retraction – Hydroxychloroquine or Chloroquine with or without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis’ ( 2020 ) 395 ( 10240 ) The Lancet 1820 <https://doi.org/10.1016/S0140-6736(20)31324-6> accessed 28 February 2021. Search in Google Scholar

Mukherjee S, The Laws of Medicine. Field Notes from an Uncertain Science (1st ed, Simon & Schuster 2015). Mukherjee S The Laws of Medicine. Field Notes from an Uncertain Science ( 1st ed , Simon & Schuster 2015 ). Search in Google Scholar

National Institutes of Health, ‘COVID-19 Treatment Guidelines’ (updated 16 December 2021) <https://www.covid19treatmentguidelines.nih.gov/statement-on-tocilizumab/> accessed 28 February 2021. National Institutes of Health ‘COVID-19 Treatment Guidelines’ (updated 16 December 2021 ) <https://www.covid19treatmentguidelines.nih.gov/statement-on-tocilizumab/> accessed 28 February 2021. Search in Google Scholar

‘Preprints’ The Lancet <https://www.thelancet.com/preprints> accessed 28 February 2021. ‘Preprints’ The Lancet <https://www.thelancet.com/preprints> accessed 28 February 2021. Search in Google Scholar

Qi R and others, ‘Case Fatality Rate of Novel Coronavirus Disease 2019 in China’ (medRxiv, 3 March 2020) <https://doi.org/10.1101/2020.02.26.20028076> accessed 20 February 2021. Qi R and others, ‘Case Fatality Rate of Novel Coronavirus Disease 2019 in China’ (medRxiv, 3 March 2020 ) <https://doi.org/10.1101/2020.02.26.20028076> accessed 20 February 2021. Search in Google Scholar

Rajgor DD and others, ‘The Many Estimates of the COVID-19 Case Fatality Rate’ (2020) 20(7) The Lancet Infectious Diseases 776 <https://doi.org/10.1016/S1473-3099(20)30244-9> accessed 20 February 2021. Rajgor DD and others, ‘The Many Estimates of the COVID-19 Case Fatality Rate’ ( 2020 ) 20 ( 7 ) The Lancet Infectious Diseases 776 <https://doi.org/10.1016/S1473-3099(20)30244-9> accessed 20 February 2021. Search in Google Scholar

Ramakrishnan S and others, ‘Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled Trial’ (medRxiv, 8 February 2021) <https://doi.org/10.1101/2021.02.04.21251134> accessed 28 February 2021. Ramakrishnan S and others, ‘Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled Trial’ (medRxiv, 8 February 2021 ) <https://doi.org/10.1101/2021.02.04.21251134> accessed 28 February 2021. Search in Google Scholar

The RECOVERY Collaborative Group, ‘Dexamethasone in Hospitalized Patients with Covid-19’ (2021) 384(8) New England Journal of Medicine 693 <https://doi.org/10.1056/NEJMoa2021436> accessed 28 February 2021. The RECOVERY Collaborative Group ‘Dexamethasone in Hospitalized Patients with Covid-19’ ( 2021 ) 384 ( 8 ) New England Journal of Medicine 693 <https://doi.org/10.1056/NEJMoa2021436> accessed 28 February 2021. Search in Google Scholar

The RECOVERY Collaborative Group, ‘Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): Preliminary Results of a Randomised, Controlled, Open-Label, Platform Trial’ (medRxiv, 11 February 2021) <https://doi.org/10.1101/2021.02.11.21249258> accessed 28 February 2021. The RECOVERY Collaborative Group ‘Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): Preliminary Results of a Randomised, Controlled, Open-Label, Platform Trial’ (medRxiv, 11 February 2021 ) <https://doi.org/10.1101/2021.02.11.21249258> accessed 28 February 2021. Search in Google Scholar

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Search in Google Scholar

Rogers A, ‘The Strange and Twisted Tale of Hydroxychloroquine’ (2020) Wired <https://www.wired.com/story/hydroxychloroquine-covid-19-strange-twisted-tale/> accessed 28 February 2021. Rogers A ‘The Strange and Twisted Tale of Hydroxychloroquine’ ( 2020 ) Wired <https://www.wired.com/story/hydroxychloroquine-covid-19-strange-twisted-tale/> accessed 28 February 2021. Search in Google Scholar

Saag MS, ‘Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics into Science’ (2020) 324(21) JAMA 2161 <https://doi.org/10.1001/jama.2020.22389> accessed 28 February 2021. Saag MS ‘Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics into Science’ ( 2020 ) 324 ( 21 ) JAMA 2161 <https://doi.org/10.1001/jama.2020.22389> accessed 28 February 2021. Search in Google Scholar

Salač J, ‘Informovaný souhlas jako nástroj vyrovnání informačního deficitu ve vztahu lékař-pacient [Informed Consent as an Instrument of Equalizing the Information Asymmetry in the Physician-Patient Relationship]’ (2019) 2(1) Paneurópske právnické listy <https://www.paneuropskepravnickelisty.sk/index.php/salac-j/> accessed 28 February 2021. Salač J ‘Informovaný souhlas jako nástroj vyrovnání informačního deficitu ve vztahu lékař-pacient [Informed Consent as an Instrument of Equalizing the Information Asymmetry in the Physician-Patient Relationship]’ ( 2019 ) 2 ( 1 ) Paneurópske právnické listy <https://www.paneuropskepravnickelisty.sk/index.php/salac-j/> accessed 28 February 2021. Search in Google Scholar

Salač J, ‘Souhlas [Consent]’ in Šustek P and Holčapek T (eds), Zdravotnické právo [Health Law] (1st ed, Wolters Kluwer 2016) 250. Salač J ‘Souhlas [Consent]’ in Šustek P Holčapek T (eds), Zdravotnické právo [Health Law] ( 1st ed, Wolters Kluwer 2016 ) 250 . Search in Google Scholar

Soderberg CK, Errington TM, and Nosek BA, ‘Credibility of Preprints: An Interdisciplinary Survey of Researchers’ (Royal Society Open Science, 28 October 2020) <https://doi.org/10.1098/rsos.201520> accessed 28 February 2021. Soderberg CK Errington TM Nosek BA ‘Credibility of Preprints: An Interdisciplinary Survey of Researchers’ ( Royal Society Open Science , 28 October 2020 ) <https://doi.org/10.1098/rsos.201520> accessed 28 February 2021. Search in Google Scholar

Šolc M, ‘Možnosti umělé inteligence při hodnocení protiprávnosti v medicínskoprávních sporech [The Possibilities of Artificial Intelligence in the Assessment of Breach of Duty in Medical Negligence Cases]’ in J Suchoža, J Husár, and R Hučková (eds), Právo, obchod, ekonomika [The Law, Commerce, and Economics] (Univerzita P. J. Šafárika v Košiciach 2020) 272. Šolc M ‘Možnosti umělé inteligence při hodnocení protiprávnosti v medicínskoprávních sporech [The Possibilities of Artificial Intelligence in the Assessment of Breach of Duty in Medical Negligence Cases]’ in Suchoža J Husár J Hučková R (eds), Právo, obchod, ekonomika [The Law, Commerce, and Economics] ( Univerzita P. J. Šafárika v Košiciach 2020 ) 272 . Search in Google Scholar

SSRN, ‘Preprints with The Lancet’ <https://www.ssrn.com/index.cfm/en/the-lancet/> accessed 28 February 2021. SSRN ‘Preprints with The Lancet’ <https://www.ssrn.com/index.cfm/en/the-lancet/> accessed 28 February 2021. Search in Google Scholar

Šustek P, ‘Náležitý odborný postup (lex artis). Obecně [Appropriate Professional Conduct (Lex Artis). General Remarks]’ in P. Šustek and T Holčapek (eds), Zdravotnické právo [Health Law] (1st ed, Wolters Kluwer 2016) 263. Šustek P ‘Náležitý odborný postup (lex artis). Obecně [Appropriate Professional Conduct (Lex Artis). General Remarks]’ in Šustek P. Holčapek T (eds), Zdravotnické právo [Health Law] ( 1st ed , Wolters Kluwer 2016 ) 263 . Search in Google Scholar

Šustek P, Holčapek T, and Šolc M, ‘Doporučení pro tzv. off-label použití léčivých přípravků pro pacienty s COVID-19 [Recommendations for the so-called off-label use of medicinal products in COVID-19 patients]’ (2020) 31(3) Anesteziologie a intenzivní medicína 119. Šustek P Holčapek T Šolc M ‘Doporučení pro tzv. off-label použití léčivých přípravků pro pacienty s COVID-19 [Recommendations for the so-called off-label use of medicinal products in COVID-19 patients]’ ( 2020 ) 31 ( 3 ) Anesteziologie a intenzivní medicína 119 . Search in Google Scholar

[‘Tweet’] The Lancet (4 June 2020) <https://twitter.com/thelancet/status/1268613313702891523> accessed 28 February 2021. [‘Tweet’] The Lancet ( 4 June 2020 ) <https://twitter.com/thelancet/status/1268613313702891523> accessed 28 February 2021. Search in Google Scholar

Venus K, Munshi L, and Fralick M, ‘Prone Positioning for Patients with Hypoxic Respiratory Failure Related to COVID-19’ (2020) 192(47) CMAJ 1532 <https://doi.org/10.1503/cmaj.201201> accessed 20 February 2021. Venus K Munshi L Fralick M ‘Prone Positioning for Patients with Hypoxic Respiratory Failure Related to COVID-19’ ( 2020 ) 192 ( 47 ) CMAJ 1532 <https://doi.org/10.1503/cmaj.201201> accessed 20 February 2021. Search in Google Scholar

Vymazal J and Šustek P, ‘Vyjádření k současné situaci s kontrastními látkami pro magnetickou rezonanci na bázi chelátů gadolinia [Statement to the Current Situation with Contrast Agents for Magnetic Resonance Imaging on the Basis of Gadolinium Chelates]’ (2017) 71(4) Česká Radiologie 260 <http://www.cesradiol.cz/detail.php?stat=615> accessed 20 February 2021. Vymazal J Šustek P ‘Vyjádření k současné situaci s kontrastními látkami pro magnetickou rezonanci na bázi chelátů gadolinia [Statement to the Current Situation with Contrast Agents for Magnetic Resonance Imaging on the Basis of Gadolinium Chelates]’ ( 2017 ) 71 ( 4 ) Česká Radiologie 260 <http://www.cesradiol.cz/detail.php?stat=615> accessed 20 February 2021. Search in Google Scholar

Weinreich DM and others, ‘REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19’ (2021) 384(3) New England Journal of Medicine 238 <https://doi.org/10.1056/NEJMoa2035002> accessed 28 February 2021. Weinreich DM and others, ‘REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19’ ( 2021 ) 384 ( 3 ) New England Journal of Medicine 238 <https://doi.org/10.1056/NEJMoa2035002> accessed 28 February 2021. Search in Google Scholar

World Health Organization, ‘“Solidarity” Clinical Trial for COVID-19 Treatments’ (11 August 2021) <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> accessed 28 February 2021. World Health Organization ‘“Solidarity” Clinical Trial for COVID-19 Treatments’ ( 11 August 2021 ) <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> accessed 28 February 2021. Search in Google Scholar

World Health Organization, ‘WHO Recommends against the Use of Remdesivir in COVID-19 Patients’ (20 November 2020) <https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients> accessed 28 February 2021. World Health Organization ‘WHO Recommends against the Use of Remdesivir in COVID-19 Patients’ ( 20 November 2020 ) <https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients> accessed 28 February 2021. Search in Google Scholar